Despite these uninspiring results, new attention has lately been put on the use of refined FTIs for cancer treatment, and as on April 2021, several clinical trials are being carried out; for example, testing Tipifarnib on tumors harboring HRAS mutations (see https://www.clinicaltrials.gov accessed on 5 April 2021, for more details). Here, HRAS is linked to cancer.